Founded in 2021, Beijing Danatlas Pharmaceutical Technology Co., Ltd. is a China-based, globally oriented innovation-driven drug R&D company. Committed to the development of "world's first (FIC)" target drugs in the era of precision targeted tumor therapy 2.0 to meet the clinical needs of patients and promote medical innovation.

       Our vision and mission is to become a leader in the development of new tumor-targeted therapies, "Chicheng Danxin" to make innovative drugs, and bring hope to mankind to "regain health".

       With a registered capital of 14.28 million yuan, the company was founded by national returnee scientists, and the founding team has rich practical experience in new drug creation and R&D management, and has led several influential innovative drugs to be listed. The core R&D team has doctoral and master's degree researchers accounting for 75% of the total number of the company.

       At present, the company has a number of world-first (FIC) new drug projects under research, with scientific research platforms such as drug design, chemical synthesis, pharmacological research, drug metabolism and safety assessment, drug analysis, patent and registration, and equipped with professional financial, HR, legal, comprehensive management and other operational support departments.